#ASH24: Chronic lymphocytic leukemia and small lymphocytic lymphoma

To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to chronic lymphocytic leukemia and small lymphocytic lymphoma, here.

CONGRESS | #ASH24 | PRESENTATION@NitinJainMD @MDAndersonNews shared data from the phase II trial of time-limited pirtobrutinib, venetoclax, and obinutuzumab in 1L #CLL. Combination of pirtobrutinib, venetoclax, and obinutuzumab showed high rate of U-MRD6 remission at 6-months… pic.twitter.com/eHHPcV3se8

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Meghan C. Thompson @MSKCancerCenter shared data from a phase II trial of MRD adapted duration of 1L venetoclax and obinutuzumab in fit patients with #CLL.
With median follow-up of 24 months, PFS was 92% and OS was 95% for the entire cohort. The… pic.twitter.com/S8eZbg3Tz1

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Jennifer R. Brown @danafarber shared interim analysis results from the phase III AMPLIFY trial of fixed-duration acalabrutinib (A) + venetoclax (V) ± obinutuzumab (O) vs chemoimmunotherapy (FCR/BR) in patients with 1L #CLL. After a median… pic.twitter.com/Z6EWoOd6e0

— Lymphoma Hub (@lymphomahub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Talha Munir @LeedsHospitals discusses results from the phase III NCRI FLAIR trial.
Results suggest that low TLS risk and unmutated IGHV status are predictors of early MRD response in patients with CLL treated with ibrutinib plus venetoclax. No new… pic.twitter.com/jxXxW3ck9K

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Anne Sophie Michallet @universitereims presents final results from the phase II ERADIC trial.
BM uMRD was not significantly lower in the IV arm vs FCR arm, however, there was improved PB uMRD and PFS in the IV arm.
Follow our live feed for more… pic.twitter.com/QHcC4s6nA6

— Lymphoma Hub (@lymphomahub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
William G. Wierda @MDAndersonNews presented data from the phase I/II TRANSCEND CLL 004 trial of lisocabtagene maraleucel (Liso-cel) + ibrutinib (Ibr) in patients with R/R #CLL/SLL.
Liso-cel + Ibr demonstrated substantial efficacy and deep… pic.twitter.com/DfUlXXaDAs

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | PRESENTATION@jeff_sharman @WVCancer shared data from the phase III BRUIN CLL-321 trial of pirtobrutinib (Pirto) vs idelalisib + rituximab (IdelaR) or bendamustine + rituximab (BR) in BTKi pretreated #CLL/SLL.
The outcomes were promising in the Pirto vs… pic.twitter.com/6I5DQa1hiv

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | PRESENTATION
Alexey Danilov @cityofhope shared data from the phase I/II EPCORE CLL-1 trial of SC epcoritamab monotherapy in heavily pretreated R/R #CLL/SLL.
SC Epcoritamab monotherapy showed deep responses regardless of the high-risk features. The ORR was… pic.twitter.com/b9QA1N7Md3

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER
Jacob D. Soumerai, @MGHCancerCenter shared long-term follow-up from the phase II BoVen trial of zanubrutinib, obinutuzumab, and venetoclax (BoVen) in treatment naïve #CLL.
Five-year follow up of the BOVen regimen demonstrates frequent uMRD4 in PB (96%)… pic.twitter.com/uqxY5ANs0v

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER
Lugui Qiu, Chinese Academy of Medical Sciences and Peking Union Medical College shared data from the phase III ChangE trial of acalabrutinib vs chlorambucil plus rituximab in TN CLL in sites across Asia.
Acalabrutinib demonstrated a clinically… pic.twitter.com/FGeWSNzlC7

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER@mshadman @fredhutch shared 5-year follow-up data from the cohort 1 of phase III SEQUOIA trial of zanubrutinib vs bendamustine + rituximab (BR) in treatment-naive CLL/SLL.
Zanubrutinib continues to demonstrate encouraging and durable efficacy vs BR,… pic.twitter.com/6bj6wf5GGl

— Lymphoma Hub (@lymphomahub) December 12, 2024

CONGRESS | #ASH24 | POSTER
William G. Wierda @MDAndersonNews presented 5.5-year follow-up data from the phase II CAPTIVATE trial of fixed-duration ibrutinib + venetoclax in patients with untreated #CLL/SLL.
Fixed-duration Ibr + Ven demonstrated durable responses with long-term… pic.twitter.com/v91DrTMS32

— Lymphoma Hub (@lymphomahub) December 11, 2024

CONGRESS | #ASH24 | POSTER
Tanya Siddiqi, @cityofhope, presented updated results from the phase I/II TRANSCEND CLL 004 (NCT03331198) trial evaluating lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated, high-risk R/R CLL/SLL (N=118). At dose level 2 (100 ×… pic.twitter.com/KeYAlFmfmq

— Lymphoma Hub (@lymphomahub) December 11, 2024